清道夫受体家族在口腔鳞状细胞癌免疫治疗中的研究进展

doi:10.19438/j.cjoms.2025.03.014

摘要/Abstract

摘要： 清道夫受体家族（scavenger receptors,SRs）属于结构异质的蛋白质超家族,参与各种疾病的发生和生物学途径,在先天免疫和体内平衡中发挥着重要功能,是调控宿主免疫功能的重要分子。口腔鳞状细胞癌（oral squamous cell carcinomas,OSCC）是最常见的口腔恶性肿瘤,近年来其患病率及死亡率呈持续上升趋势,并且越来越年轻化。靶向治疗和免疫治疗在口腔癌尤其是晚期口腔癌的治疗中展现出巨大潜力,免疫治疗联合化疗的新辅助治疗模式具有较好的安全性和有效性,可以在不影响患者预后的前提下缩短手术时间,减小手术创伤。本文针对目前关于清道夫受体家族与OSCC免疫治疗的研究进展进行综述,以期为OSCC的免疫治疗提供参考。

关键词: 清道夫受体家族, 口腔鳞状细胞癌, 免疫治疗, 免疫治疗联合化疗

Abstract: Scavenger receptors is a superfamily of proteins with heterogeneous structure, which is involved in the occurrence and biological pathways of various diseases, plays an important role in innate immunity and homeostasis, and is an important molecule regulating host immune function. Oral squamous cell carcinomaOSCC) is one of the most common malignancies in oral cavity. In recent years, the prevalence and mortality of oral cancer have been on the rise, and more common in younger population. Targeted therapy and immunotherapy have shown great potential in the treatment of oral cancer, especially in advanced oral cancer. The neoadjuvant treatment mode of immunotherapy combined with chemotherapy has good safety and effectiveness, which can shorten the operation time and reduce the surgical trauma without affecting the prognosis of patients. This article mainly reviewed the current research progress on scavenger receptor family and OSCC immunotherapy, in order to provide more potential immunotherapy targets for the treatment of OSCC.

Key words: Scavenger receptors, Oral squamous cell carcinoma, Immunotherapy, Immunotherapy combined with chemotherapy

中图分类号:

R739.8

李红云, 段晓峰. 清道夫受体家族在口腔鳞状细胞癌免疫治疗中的研究进展[J]. 中国口腔颌面外科杂志, 2025, 23(3): 297-301.

Li Hongyun, Duan Xiaofeng. Research progress of scavenger receptor family in immunotherapy for oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2025, 23(3): 297-301.

参考文献

[1] Patel V, Galloway TJ, Liu JC.The impact of positive margin on survival in oral cavity squamous cell carcinoma[J]. Oral Oncol, 2021, 122: 105499.
[2] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3] Ng JH, Iyer NG, Tan MH, et al.Changing epidemiology of oral squamous cell carcinoma of the tongue: a global study[J]. Head Neck, 2017, 39(2): 297-304.
[4] Tan Y, Wang Z, Xu M, et al.Oral squamous cell carcinomas: state of the field and emerging directions[J]. Int J Oral Sci, 2023, 15(1): 44.
[5] Chamoli A, Gosavi AS, Shirwadkar UP, et al.Overview of oral cavity squamous cell carcinoma: risk factors, mechanisms, and diagnostics[J]. Oral Oncol, 2021, 121: 105451.
[6] Jemal A, Bray F, Center MM, et al.Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[7] Taban Q, Mumtaz PT, Masoodi KZ, et al.Scavenger receptors in host defense: from functional aspects to mode of action[J]. Cell Commun Signal, 2022, 20(1): 2-18.
[8] Kazakova E, Iamshchikov P, Larionova I, et al.Macrophage scavenger receptors: tumor support and tumor inhibition[J]. Front Oncol, 2023, 12: 1096897.
[9] Brown MS, Goldstein JL.Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis[J]. Annu Rev Biochem, 1983, 52: 223-261.
[10] Patten DA, Wilkinson AL, O'Keeffe A, et al. Scavenger receptors: novel roles in the pathogenesis of liver inflammation and cancer[J]. Semin Liver Dis, 2022, 42(1): 61-76.
[11] Plüddemann A, Mukhopadhyay S, Gordon S.Innate immunity to intracellular pathogens: macrophage receptors and responses to microbial entry[J]. Immunol Rev, 2011, 240(1): 11-24.
[12] PrabhuDas MR, Baldwin CL, Bollyky PL, et al. A consensus definitive classification of scavenger receptors and their roles in health and disease[J]. J Immunol, 2017, 198(10): 3775-3789.
[13] Zani IA, Stephen SL, Mughal NA, et al.Scavenger receptor structure and function in health and disease[J]. Cells, 2015, 4(2): 178-201.
[14] Tillison EA, Sahoo D.Sticky business: correlating oligomeric features of Class B scavenger receptors to lipid transport[J]. Curr Atheroscler Rep, 2024, 27(1): 15.
[15] Velasco-de Andrés M, Casadó-Llombart S, Català C, et al. Soluble CD5 and CD6: lymphocytic Class I scavenger receptors as immunotherapeutic agents[J]. Cells, 2020, 9(12): 2589.
[16] Vasquez M, Simões I, Consuegra-Fernández M, et al.Exploiting scavenger receptors in cancer immunotherapy: lessons from CD5 and SR-B1[J]. Eur J Immunol, 2017, 47(7): 1108-1118.
[17] Gudgeon J, Marín-Rubio JL, Trost M.The role of macrophage scavenger receptor 1 (MSR1) in inflammatory disorders and cancer[J]. Front Immunol, 2022, 13: 1012002.
[18] Haidari S, Tröltzsch M, Knösel T, et al.Fatty acid receptor CD36 functions as a surrogate parameter for lymph node metastasis in oral squamous cell carcinoma[J]. Cancers (Basel), 2021, 13(16): 4125.
[19] Sakurai K, Tomihara K, Yamazaki M, et al.CD36 expression on oral squamous cell carcinoma cells correlates with enhanced proliferation and migratory activity[J]. Oral Dis, 2020, 26(4): 745-755.
[20] Wang Y, Zhang X, Wang S, et al.Identification of metabolism-associated biomarkers for early and precise diagnosis of oral squamous cell carcinoma[J]. Biomolecules, 2022, 12(3): 400.
[21] Zhang J, Li S, Liu F, et al.Role of CD68 in tumor immunity and prognosis prediction in pan-cancer[J]. Sci Rep, 2022, 12(1): 7844.
[22] Yamagata Y, Tomioka H, Sakamoto K, et al.CD163-positive macrophages within the tumor stroma are associated with lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma[J]. J Oral Maxillofac Surg, 2017, 75(10): 2144-2153.
[23] Ni YH, Ding L, Huang XF, et al.Microlocalization of CD68+ tumor-associated macrophages in tumor stroma correlated with poor clinical outcomes in oral squamous cell carcinoma patients[J]. Tumour Biol, 2015, 36(7): 5291-5298.
[24] Kazakova E, Iamshchikov P, Larionova I, et al.Macrophage scavenger receptors: tumor support and tumor inhibition[J]. Front Oncol, 2023, 12: 1096897.
[25] Haque ASMR, Moriyama M, Kubota K, et al.CD206+ tumor-associated macrophages promote proliferation and invasion in oral squamous cell carcinoma via EGF production[J]. Sci Rep, 2019, 9(1): 14611.
[26] Rabinowits G, Haddad RI.Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature[J]. Oral Oncol, 2012, 48(11): 1085-1089.
[27] Schledzewski K, Géraud C, Arnold B, et al.Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors[J]. J Clin Invest, 2011, 121(2): 703-714.
[28] Irjala H, Alanen K, Grénman R, et al.Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor(CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium[J]. Cancer Res, 2003, 63(15): 4671-4676.
[29] Buechler C, Ritter M, Orsó E, et al.Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli[J]. J Leukoc Biol, 2000, 67(1): 97-103.
[30] Han MW, Lee JC, Park SY, et al.Homotypic interaction of Stabilin-2 plays a critical role in lymph node metastasis of tongue cancer[J]. Anticancer Res, 2016, 36(12): 6611-6618.
[31] Chohan MH, Perry M, Laurance-Young P, et al.Prognostic role of CD68+ and CD163+ tumour-associated macrophages and PD-L1 expression in oral squamous cell carcinoma: a meta-analysis[J]. Br J Biomed Sci, 2023, 80: 11065.
[32] Kubota K, Moriyama M, Furukawa S, et al.CD163+ CD204+ tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma[J]. Sci Rep, 2017, 7(1): 1755.
[33] Su S, Chien M, Lin C, et al.RAGE gene polymorphism and environmental factor in the risk of oral cancer[J]. J Dent Res, 2015, 94(3): 403-411.
[34] Joosten SPJ, Spaargaren M, Clevers H, et al.Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(2): 188437.
[35] Wang SJ, Bourguignon LY.Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance[J]. Am J Pathol, 2011, 178(3): 956-963.
[36] Herz J, Strickland DK.LRP: a multifunctional scavenger and signaling receptor[J]. J Clin Invest, 2001, 108(6): 779-784.
[37] Chea C, Miyauchi M, Inubushi T, et al.Molecular mechanisms of inhibitory effects of bovine lactoferrin on invasion of oral squamous cell carcinoma[J]. Pharmaceutics, 2023, 15(2): 562.
[38] Kubota K, Moriyama M, Furukawa S, et al.CD163+ CD204+ tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma[J]. Sci Rep, 2017, 7(1): 1755.
[39] Wang CW, Biswas PK, Islam A, et al.The use of immune regulation in treating head and neck squamous cell carcinoma (HNSCC)[J]. Cells, 2024, 13(5): 413.
[40] Lee Y, Shin JH, Longmire M, et al.CD44+ cells in head and neck squamous cell carcinoma suppress T-cell-mediated immunity by selective constitutive and inducible expression of PD-L1[J]. Clin Cancer Res, 2016, 22(14): 3571-3581.
[41] Bhaskaran N, Jayaraman S, Quigley C, et al.The role of Dectin-1 signaling in altering tumor immune microenvironment in the context of aging[J]. Front Oncol, 2021, 11: 669066.
[42] He Y, Dong Y, Zhang X, et al.Lipid droplet-related PLIN2 in CD68+ tumor-associated macrophage of oral squamous cell carcinoma: implications for cancer prognosis and immunotherapy[J]. Front Oncol, 2022, 12: 824235.
[43] Su W, Wang Y, Wang F, et al.Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway[J]. BMC Cancer, 2019, 19(1): 400.
[44] Liang J, Liu J, Deng Z, et al.DLX6 promotes cell proliferation and survival in oral squamous cell carcinoma[J]. Oral Dis, 2022, 28(1): 87-96.
[45] Jin H, Zhang L, Wang S, et al.BST2 promotes growth and induces gefitinib resistance in oral squamous cell carcinoma via regulating the EGFR pathway[J]. Arch Med Sci, 2019, 17(6): 1772-1782.
[46] Xie H, Ma Y, Li J, et al.WNT7A promotes EGF-induced migration of oral squamous cell carcinoma cells by activating β-catenin/MMP9-mediated signaling[J]. Front Pharmacol, 2020, 11: 98.
[47] Sasahira T, Kirita T, Bhawal UK, et al.Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma[J]. Histopathology, 2007, 51(2): 166-172.
[48] Ko SY, Ko HA, Shieh TM, et al.Cell migration is regulated by AGE-RAGE interaction in human oral cancer cells in vitro[J]. PLoS One, 2014, 9(10): e110542.
[49] Plemmenos G, Tzimogianni V, Fili C, et al.Contributing role of high mobility group box 1 signaling in oral cancer development and therapy[J]. Life (Basel), 2023, 13(7): 1577.
[50] Riley RS, June CH, Langer R, et al.Delivery technologies for cancer immunotherapy[J]. Nat Rev Drug Discov, 2019, 18(3): 175-196.
[51] 靳能皓, 田瑜, 朱亮, 等. PD-L1及肿瘤免疫微环境对预测口腔鳞癌新辅助治疗效果的意义[J]. 中国口腔颌面外科杂志, 2023, 21(6): 572-578.
Jin NH, Tian Y, Zhu L, et al.Clinical significance of PD-L1 and tumor immune microenvironment in predicting neoadjuvant therapy for oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(6): 572-578.
[52] 孙立伟, 李林, 李金铎, 等. 头颈部鳞状细胞癌的免疫治疗进展[J]. 中国城乡企业卫生, 2023, 38(7): 47-50.
Sun LW, Li L, Li JD, et al.Progress in immunotherapy of head and neck squamous cell carcinoma[J]. Chinese Journal of Urban and Rural Enterprise Hygiene, 2023, 38(7): 47-50.
[53] Cheng Y, Song Z, Chen J, et al.Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods[J]. Heliyon, 2024, 10(4): e25895.
[54] Clarke E, Eriksen JG, Barrett S.The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis[J]. Acta Oncol, 2021, 60(11): 1534-1542.
[55] 汪子恒, 周韧, 严佳, 等. 靶向EGFR治疗联合化疗与单纯化疗对口腔癌痛的影响[J]. 中国口腔颌面外科杂志, 2023, 21(3): 225-230.
Wang ZH, Zhou R, Yan J, et al.Effect of EGFR-targeted therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain[J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(3): 225-230.
[56] 许婷婷, 胡超苏, 李宝生. 抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识(2023年版)[J]. 中国癌症, 2023, 33(1): 81-94.
Xu TT, Hu CS, Li BS.Clinical consensus on the treatment of locally advanced squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody(2023 edition)[J]. China Oncology, 2023, 33(1): 81-94.
[57] Chen L, Ling Y, Yang H.Comprehensive analysis of the potential prognostic value of 11 glycosylation-related genes in head and neck squamous cell carcinoma and their correlation with PD-L1 expression and immune infiltration[J]. J Oncol, 2022: 2786680.